Clinical trials: Renal Allograft Recipients
Kidney Transplantation
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with…
- Trial name
- NCT00782821
- Testing
- Rabbit Antithymocyte Globulin, Velcade, Rituxan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Kidney Transplant
A Study Of CP-690,550 In Stable Kidney Transplant Patients
This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients.
- Trial name
- NCT01710033
- Testing
- CP-690,550 5 mg BID, CP-690,550 15 mg BID, CP-690,550 30 mg BID
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Transplantation, Kidney, Living Donors
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
The aim of this study is to determine a comprehensive immune profile of transplant donors and recipients through assessment of immune cell compositions in bone marrow, and lymph nodes.
- Conditions
- Transplantation, Kidney, Living Donors, Kidney Transplant Recipients
- Trial name
- NCT01150487
- Testing
- bone marrow aspirations, lymph node collection
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Mayo Clinic
Pharmacokinetics Study in de Novo Kidney Transplantation
Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients
The purpose of this study was to investigate if Tacrolimus Hexal® has similar pharmacokinetic properties compared to Prograf® in de novo renal transplant patients and whether the comparable exposure resulted in similar renal…
- Trial name
- Spartacus (NCT01649427)
- Testing
- Prograf, Tacrolimus Hexal
- Where
- 5 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Renal Failure
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
- Trial name
- NCT01666951
- Testing
- LCP-Tacro tablets, Prograf
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Veloxis Pharmaceuticals
Epstein-Barr Virus Infections
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Epstein Barr virus infects over 90% of human population and persists during lifetime. After infecting B lymphocytes, EBV remains latent in memory B cells.
- Trial name
- REPLY (NCT04989491)
- Testing
- Rituximab, control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Cardiorenal Syndrome, Chronic Allograft Nephropathy
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac…
- Trial name
- NCT01265615
- Testing
- Paricalcitol, Calcitriol, Cholecalciferol
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 109 people
- Sponsor
- Ural State Medical University
Chronic Allograft Injury
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
The main purpose of the study is to investigate the safety and tolerability of repeat dosing with zampilimab in kidney transplant recipients with deteriorating kidney function associated with chronic allograft injury (CAI).
- Trial name
- NCT04335578
- Testing
- Zampilimab
- Where
- 5 sites in Australia, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- UCB Biopharma SRL
Kidney Transplantation, Kidney Failure
Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis
Development of chronic changes (scarring) in transplanted kidney tissue is a major cause of long-term kidney function deterioration and ultimately graft loss. It results from both immunologic and non-immunologic mechanisms.
- Trial name
- NCT01860183
- Testing
- Mycophenolate mofetil
- Where
- Croatia
- Volunteers
- 76 people
- Sponsor
- Clinical Hospital Merkur
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
HBsAg-positive Renal Allograft Recipients
Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.
The hepatitis B virus (HBV) infection rate among renal transplant recipients was reported from 3% to 20.9%. And patient survival and graft survival rates following renal transplantation may be worsen in HBsAg-positive carriers…
- Trial name
- NCT02894554
- Testing
- Telbivudine, Lamivudine
- Volunteers
- 19 people
- Sponsor
- National Taiwan University Hospital
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
The objective of this study is to examine the effect on allograft function and histology of converting African American renal transplant recipients with chronic allograft nephropathy (CAN) from a tacrolimus-based regimen to a…
- Trial name
- NCT00999258
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Temple University
Kidney Transplant Recipients
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn.
- Trial name
- NCT01517984
- Testing
- Tacrolimus (CNI) Withdrawal, Standard Immunosuppressive Therapy
- Where
- 11 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Failure
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
An open-label study to assess the safety, efficacy, and tolerance of FCRx cell therapy in adult recipients within 12 months after kidney transplantation from a living donor.
- Trial name
- NCT00497926
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Talaris Therapeutics Inc.
Cytomegalovirus Infections
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
This is a Phase II, randomized, double-blind, placebo-controlled study designed to assess the safety and clinical activity of multiple intravenous doses of MCMV5322A/MCMV3068A in cytomegalovirus (CMV)-seronegative recipients of a…
- Trial name
- NCT01753167
- Testing
- MCMV3068A, MCMV5322A
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Primary Renal Allograft
Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
Evaluate the safety and efficacy of early corticosteroid withdrawal and simultaneous calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on MMF and sirolimus.
- Trial name
- NCT00374647
- Testing
- mycophenolate mofetil, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Cincinnati
Kidney Transplant
Long-term Follow-up of Spare the Nephron (STN) Patients
Allograft nephropathy is the most common cause of allograft failure following kidney transplantation. Among putative etiologies, cumulative exposure to calcineurin inhibitors may be one of the important progression factors.
- Trial name
- STN (NCT01126333)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Maryland, Baltimore
Chronic Allograft Nephropathy
Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function
The purpose of this trial is to ascertain whether the withdrawal of calcineurin inhibitors (CNI) will lead to less kidney transplant damage when compared with minimisation.
- Trial name
- CNIM-SRT (NCT00541814)
- Testing
- Cyclosporine
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University Hospital Birmingham
Kidney Transplant; Complications
Esomeprazole or Pantoprazole in Renal Transplantation
prospective, parallel, open-label clinical trial was performed on forty-seven adult renal transplant recipients receiving immunosuppressive therapy with CsA doses adjusted to attain trough concentrations of 100-150 μg/L…
- Trial name
- NCT03812419
- Testing
- Esomeprazole 40 mg, Pantoprazole 40mg
- Volunteers
- 47 people
- Sponsor
- Future University in Egypt